The overall hypothesis guiding the OHSU Blood-Brain Barrier (BBB) Program for the past three decades has been that the BBB and blood-tumor barrier, as well as the blood-cerebral spinal fluid (CSF) barrier, limit agent delivery and therefore dose intensity in brain tumors. We have tested the hypothesis that increased dose intensity may be achieved by increasing drug delivery to brain tumor with osmotic BBB disruption (BBBD). Another approach to increasing dose intensity is to deplete glutathione, an endogenous anti-oxidant which inactivates alkylating chemotherapeutics. Since dose intensification can increase chemotherapy toxic side effects, we will use thiols that mimic the activity of glutathione, including sodium thiosulfate and N- acetylcysteine, to reduce chemotherapy toxicities, as we have during the last 8 years of this Javits Award.
In Specific Aim 1 of this revised proposal, we will assess the potential for enhancing chemotherapy dose intensity for intracerebral medulloblastoma as a model of primitive neuroectodermal tumors within brain parenchyma, by using BBBD and by depleting glutathione stores in conjunctions with thiol rescue. Additionally we will evaluate new imaging techniques for assessing efficacy in solid brain tumors. These studies will test the hypothesis that lowering glutathione concentrations will safely improve alkylating chemotherapy efficacy.
Specific Aim 2 will utilize the chemo-enhancement and protection strategies of Aim 1 to improve alkylating chemotherapy efficacy against disseminated medulloblastoma in the leptomeninges and CSF, and will use novel imaging techniques to monitor hydrocephalus and chemotherapy efficacy.
Specific Aim 3 will evaluate thiol chemoprotection for models of platinum-induced ototoxicity. We hypothesize that thiol chemoprotection separated from chemotherapy by timing, route of administration, and utilizing the neurovascular barriers, will allow increased chemotherapy doses while reducing chemotherapy toxicity in normal tissues.
Specific Aim 4 will translate the chemoprotection and enhanced delivery into a Phase I/II clinical trial in CNS embryonal tumors. Our overall hypothesis is that by modulating the timing and route of administration of chemo-enhancers, chemotherapy, and chemoprotection, toxicity at the blood-neural barriers can be decreased while increasing anti-tumor efficacy.

Public Health Relevance

We hypothesize that increased dose intensity in chemotherapy sensitive brain tumors such as primitive neuroectodermal tumors (PNET), may be achieved by increasing drug activity using chemo-enhancers, decreasing non-specific drug cytotoxicity using chemoprotectors that do not cross the blood-brain barrier (BBB), and increasing chemotherapy drug delivery to brain tumor with osmotic BBB disruption.
Aims 1 -3 are preclinical studies of modulating glutathione, and aim 4 will be clinical trials of thiol chemoprotection with the goal of testing chemo-enhancement in brain tumor subjects.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Brain Injury and Neurovascular Pathologies Study Section (BINP)
Program Officer
Jacobs, Tom P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Schools of Medicine
United States
Zip Code
Hamilton, Bronwyn E; Woltjer, Randall L; Prola-Netto, Joao et al. (2016) Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations. J Neurooncol 129:301-9
Netto, Joao Prola; Schwartz, Daniel; Varallyay, Csanad et al. (2016) Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab. Fluids Barriers CNS 13:23
McConnell, Heather L; Schwartz, Daniel L; Richardson, Brian E et al. (2016) Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. Nanomedicine 12:1535-42
Muldoon, Leslie L; Pagel, Michael A; Netto, Joao Prola et al. (2016) Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. J Neurooncol 126:447-54
Muldoon, Leslie L; Wu, Y Jeffrey; Pagel, Michael A et al. (2015) N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. J Neurooncol 121:433-40
Lal, Sangeet; Kersch, Cymon; Beeson, Kathleen A et al. (2015) Interactions between ?v-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain. PLoS One 10:e0131842
Pishko, Gregory L; Muldoon, Leslie L; Pagel, Michael A et al. (2015) Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids Barriers CNS 12:5
Doolittle, Nancy D; Muldoon, Leslie L; Culp, Aliana Y et al. (2014) Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol 71:203-43
Gahramanov, Seymur; Varallyay, Csanad; Tyson, Rose Marie et al. (2014) Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncol 3:389-400
Neuwelt, Alexander J; Nguyen, Tam; Wu, Y Jeffrey et al. (2014) Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors. Pediatr Blood Cancer 61:120-7

Showing the most recent 10 out of 53 publications